Cargando…
剂量调整的EP(D)OCH方案联合利妥昔单抗治疗新诊断双表达淋巴瘤的疗效分析
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342966/ https://www.ncbi.nlm.nih.gov/pubmed/28655103 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.06.017 |
_version_ | 1783555650402385920 |
---|---|
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-7342966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Editorial office of Chinese Journal of Hematology |
record_format | MEDLINE/PubMed |
spelling | pubmed-73429662020-07-16 剂量调整的EP(D)OCH方案联合利妥昔单抗治疗新诊断双表达淋巴瘤的疗效分析 Zhonghua Xue Ye Xue Za Zhi 短篇论著 Editorial office of Chinese Journal of Hematology 2017-06 /pmc/articles/PMC7342966/ /pubmed/28655103 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.06.017 Text en 2017年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal. |
spellingShingle | 短篇论著 剂量调整的EP(D)OCH方案联合利妥昔单抗治疗新诊断双表达淋巴瘤的疗效分析 |
title | 剂量调整的EP(D)OCH方案联合利妥昔单抗治疗新诊断双表达淋巴瘤的疗效分析 |
title_full | 剂量调整的EP(D)OCH方案联合利妥昔单抗治疗新诊断双表达淋巴瘤的疗效分析 |
title_fullStr | 剂量调整的EP(D)OCH方案联合利妥昔单抗治疗新诊断双表达淋巴瘤的疗效分析 |
title_full_unstemmed | 剂量调整的EP(D)OCH方案联合利妥昔单抗治疗新诊断双表达淋巴瘤的疗效分析 |
title_short | 剂量调整的EP(D)OCH方案联合利妥昔单抗治疗新诊断双表达淋巴瘤的疗效分析 |
title_sort | 剂量调整的ep(d)och方案联合利妥昔单抗治疗新诊断双表达淋巴瘤的疗效分析 |
topic | 短篇论著 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342966/ https://www.ncbi.nlm.nih.gov/pubmed/28655103 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.06.017 |
work_keys_str_mv | AT jìliàngdiàozhěngdeepdochfāngànliánhélìtuǒxīdānkàngzhìliáoxīnzhěnduànshuāngbiǎodálínbāliúdeliáoxiàofēnxī AT jìliàngdiàozhěngdeepdochfāngànliánhélìtuǒxīdānkàngzhìliáoxīnzhěnduànshuāngbiǎodálínbāliúdeliáoxiàofēnxī AT jìliàngdiàozhěngdeepdochfāngànliánhélìtuǒxīdānkàngzhìliáoxīnzhěnduànshuāngbiǎodálínbāliúdeliáoxiàofēnxī AT jìliàngdiàozhěngdeepdochfāngànliánhélìtuǒxīdānkàngzhìliáoxīnzhěnduànshuāngbiǎodálínbāliúdeliáoxiàofēnxī AT jìliàngdiàozhěngdeepdochfāngànliánhélìtuǒxīdānkàngzhìliáoxīnzhěnduànshuāngbiǎodálínbāliúdeliáoxiàofēnxī AT jìliàngdiàozhěngdeepdochfāngànliánhélìtuǒxīdānkàngzhìliáoxīnzhěnduànshuāngbiǎodálínbāliúdeliáoxiàofēnxī AT jìliàngdiàozhěngdeepdochfāngànliánhélìtuǒxīdānkàngzhìliáoxīnzhěnduànshuāngbiǎodálínbāliúdeliáoxiàofēnxī AT jìliàngdiàozhěngdeepdochfāngànliánhélìtuǒxīdānkàngzhìliáoxīnzhěnduànshuāngbiǎodálínbāliúdeliáoxiàofēnxī AT jìliàngdiàozhěngdeepdochfāngànliánhélìtuǒxīdānkàngzhìliáoxīnzhěnduànshuāngbiǎodálínbāliúdeliáoxiàofēnxī AT jìliàngdiàozhěngdeepdochfāngànliánhélìtuǒxīdānkàngzhìliáoxīnzhěnduànshuāngbiǎodálínbāliúdeliáoxiàofēnxī AT jìliàngdiàozhěngdeepdochfāngànliánhélìtuǒxīdānkàngzhìliáoxīnzhěnduànshuāngbiǎodálínbāliúdeliáoxiàofēnxī AT jìliàngdiàozhěngdeepdochfāngànliánhélìtuǒxīdānkàngzhìliáoxīnzhěnduànshuāngbiǎodálínbāliúdeliáoxiàofēnxī |